Chand, Meera

Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant

Lopez Bernal, J., Andrews, N., Gower, C., Gallagher, E., Simmons, R., Thelwall, S., Stowe, J., Tessier, E., Groves, N., Dabrera, G., et al. (2021) · New England Journal of Medicine

SARS-CoV-2 and COVID-19 ResearchVaccine Coverage and Hesitancy

Cited by 2,889

Effectiveness of COVID-19 vaccines against the B.1.617.2 variant

Bernal, J. L., Andrews, N., Gower, C., Gallagher, E., Simmons, R., Thelwall, S., Stowe, J., Tessier, E., Groves, N., Dabrera, G., et al. (2021) · New England Journal of Medicine

SARS-CoV-2 and COVID-19 ResearchVaccine Coverage and Hesitancy

Cited by 2,888

Effectiveness of COVID-19 vaccines against the Omicron (B.1.1.529) variant of concern

Andrews, N., Stowe, J., Kirsebom, F., Toffa, S., Rickeard, T., Gallagher, E., Gower, C., Kall, M., Groves, N., O’Connell, A.-M., et al. (2021) · New England Journal of Medicine

SARS-CoV-2 and COVID-19 ResearchVaccine Coverage and Hesitancy

Cited by 2,420

Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England

The COVID-19 Genomics UK (COG-UK) consortium, Volz, E., Mishra, S., Chand, M., Barrett, J. C., Johnson, R., Geidelberg, L., Hinsley, W. R., Laydon, D. J., Dabrera, G., et al. (2021) · Nature

SARS-CoV-2 and COVID-19 ResearchCOVID-19 epidemiological studies

Cited by 1,611

Transmission of SARS-CoV-2 Lineage B.1.1.7 in England: Insights from linking epidemiological and genetic data

Volz, E., Mishra, S., Chand, M., Barrett, J. C., Johnson, R., Geidelberg, L., Hinsley, W. R., Laydon, D. J., Dabrera, G., O’Toole, Á., et al. (2021) · Nature

SARS-CoV-2 and COVID-19 ResearchCOVID-19 epidemiological studies

Cited by 1,611

SARS-CoV-2 evolution during treatment of chronic infection

Kemp, S. A., Collier, D. A., Datir, R. P., Ferreira, I. A. T. M., Gayed, S., Jahun, A., Hosmillo, M., Rees-Spear, C., Mlcochova, P., Lumb, I. U., et al. (2021) · Nature

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies

Cited by 1,097

Evaluating the Effects of SARS-CoV-2 Spike Mutation D614G on Transmissibility and Pathogenicity

Volz, E., Hill, V., McCrone, J. T., Price, A., Jorgensen, D., O’Toole, Á., Southgate, J., Johnson, R., Jackson, B., Nascimento, F. F., et al. (2021) · Cell

SARS-CoV-2 and COVID-19 ResearchEvolution and Genetic Dynamics

Cited by 1,006

Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers

Lumley, S. F., O’Donnell, D., Stoesser, N. E., Matthews, P. C., Howarth, A., Hatch, S. B., Marsden, B. D., Cox, S., James, T., Warren, F., et al. (2021) · New England Journal of Medicine

SARS-CoV-2 and COVID-19 ResearchCOVID-19 epidemiological studies

Cited by 940

SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses

Dejnirattisai, W., Huo, J., Zhou, D., Zahradník, J., Supasa, P., Liu, C., Duyvesteyn, H. M. E., Ginn, H. M., Mentzer, A. J., Tuekprakhon, A., et al. (2022) · Cell

SARS-CoV-2 and COVID-19 Researchvaccines and immunoinformatics approaches

Cited by 930

Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines

Andrews, N., Tessier, E., Stowe, J., Gower, C., Kirsebom, F., Simmons, R., Gallagher, E., Thelwall, S., Groves, N., Dabrera, G., et al. (2022) · New England Journal of Medicine

SARS-CoV-2 and COVID-19 ResearchVaccine Coverage and Hesitancy

Cited by 807

Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study

Twohig, K. A., Nyberg, T., Zaidi, A., Thelwall, S., Sinnathamby, M. A., Aliabadi, S., Seaman, S. R., Harris, R. J., Hope, R., Lopez-Bernal, J., et al. (2022) · The Lancet Infectious Diseases

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies

Cited by 803

SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway

Willett, B. J., Grove, J., MacLean, O. A., Wilkie, C., De Lorenzo, G., Furnon, W., Cantoni, D., Scott, S., Logan, N., Ashraf, S., et al. (2022) · Nature Microbiology

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies

Cited by 785

COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study

Hall, V. J., Foulkes, S., Saei, A., Andrews, N., Oguti, B., Charlett, A., Wellington, E., Stowe, J., Gillson, N., Atti, A., et al. (2021) · The Lancet

SARS-CoV-2 and COVID-19 ResearchVaccine Coverage and Hesitancy

Cited by 767

Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies

Collier, D. A., De Marco, A., Ferreira, I. A. T. M., Meng, B., Datir, R. P., Walls, A. C., Kemp, S. A., Bassi, J., Pinto, D., Silacci-Fregni, C., et al. (2021) · Nature

SARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections Studies

Cited by 728

Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection

Hall, V., Foulkes, S., Insalata, F., Kirwan, P., Saei, A., Atti, A., Wellington, E., Khawam, J., Munro, K., Cole, M., et al. (2022) · New England Journal of Medicine

SARS-CoV-2 and COVID-19 ResearchCOVID-19 epidemiological studies

Cited by 711

SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN)

Hall, V. J., Foulkes, S., Charlett, A., Atti, A., Monk, E. J. M., Simmons, R., Wellington, E., Cole, M. J., Saei, A., Oguti, B., et al. (2021) · The Lancet

SARS-CoV-2 and COVID-19 ResearchCOVID-19 epidemiological studies

Cited by 638

Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine

Payne, R. P., Longet, S., Austin, J. A., Skelly, D. T., Dejnirattisai, W., Adele, S., Meardon, N., Faustini, S., Al-Taei, S., Moore, S. C., et al. (2021) · Cell

SARS-CoV-2 and COVID-19 ResearchImmune responses and vaccinations

Cited by 322

Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B.1.1.7: an ecological study

Graham, M. S., Sudre, C. H., May, A., Antonelli, M., Murray, B., Varsavsky, T., Kläser, K., Canas, L. S., Molteni, E., Modat, M., et al. (2021) · The Lancet Public Health

SARS-CoV-2 and COVID-19 ResearchCOVID-19 epidemiological studies

Cited by 304

GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19

Pairo-Castineira, E., Rawlik, K., Bretherick, A. D., Qi, T., Wu, Y., Nassiri, I., McConkey, G. A., Zechner, M., Klaric, L., Griffiths, F., et al. (2023) · Nature

Genetic Associations and EpidemiologyCOVID-19 Clinical Research Studies

Cited by 225

COVID-19 vaccine effectiveness against the omicron (BA.2) variant in England

Kirsebom, F. C. M., Andrews, N., Stowe, J., Toffa, S., Sachdeva, R., Gallagher, E., Groves, N., O'Connell, A.-M., Chand, M., Ramsay, M., et al. (2022) · The Lancet Infectious Diseases

SARS-CoV-2 and COVID-19 ResearchCOVID-19 epidemiological studies

Cited by 182

Cloth Lanyards as a Source of Intermittent Transmission of Candida auris on an ICU*

Patterson, C. A., Wyncoll, D., Patel, A., Ceesay, Y., Newsholme, W., Chand, M., Mitchell, H., Tan, M., & Edgeworth, J. D. (2021) · Critical Care Medicine

Infection Control in HealthcareAntifungal resistance and susceptibility

Cited by 32

Effectiveness of the COVID-19 vaccines against hospitalisation with Omicron sub-lineages BA.4 and BA.5 in England

Møller Kirsebom, F. C., Andrews, N., Stowe, J., Groves, N., Chand, M., Ramsay, M., & Bernal, J. L. (2022) · The Lancet Regional Health - Europe

SARS-CoV-2 and COVID-19 ResearchCOVID-19 epidemiological studies

Cited by 31